Exact Mass: 749.5722949999999
Exact Mass Matches: 749.5722949999999
Found 442 metabolites which its exact mass value is equals to given mass value 749.5722949999999,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
PE(P-16:0/22:5(4Z,7Z,10Z,13Z,16Z))
PE(P-16:0/22:5(4Z,7Z,10Z,13Z,16Z)) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(P-16:0/22:5(4Z,7Z,10Z,13Z,16Z)), in particular, consists of one chain of plasmalogen 16:0 at the C-1 position and one chain of docosapentaenoic acid at the C-2 position. The plasmalogen 16:0 moiety is derived from animal fats, liver and kidney, while the docosapentaenoic acid moiety is derived from animal fats and brain. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PEs are neutral zwitterions at physiological pH. They mostly have palmitic or stearic acid on carbon 1 and a long chain unsaturated fatty acid (e.g. 18:2, 20:4 and 22:6) on carbon 2. PE synthesis can occur via two pathways. The first requires that ethanolamine be activated by phosphorylation and then coupled to CDP. The ethanolamine is then transferred from CDP-ethanolamine to phosphatidic acid to yield PE. The second involves the decarboxylation of PS. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids.
PE(20:4(5Z,8Z,11Z,14Z)/P-18:1(11Z))
PE(20:4(5Z,8Z,11Z,14Z)/P-18:1(11Z)) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(20:4(5Z,8Z,11Z,14Z)/P-18:1(11Z)), in particular, consists of one chain of arachidonic acid at the C-1 position and one chain of plasmalogen 18:1n7 at the C-2 position. The arachidonic acid moiety is derived from animal fats and eggs, while the plasmalogen 18:1n7 moiety is derived from animal fats, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PEs are neutral zwitterions at physiological pH. They mostly have palmitic or stearic acid on carbon 1 and a long chain unsaturated fatty acid (e.g. 18:2, 20:4 and 22:6) on carbon 2. PE synthesis can occur via two pathways. The first requires that ethanolamine be activated by phosphorylation and then coupled to CDP. The ethanolamine is then transferred from CDP-ethanolamine to phosphatidic acid to yield PE. The second involves the decarboxylation of PS. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids. PE(20:4(5Z,8Z,11Z,14Z)/P-18:1(11Z)) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(20:4(5Z,8Z,11Z,14Z)/P-18:1(11Z)), in particular, consists of one chain of arachidonic acid at the C-1 position and one chain of plasmalogen 18:1n7 at the C-2 position. The arachidonic acid moiety is derived from animal fats and eggs, while the plasmalogen 18:1n7 moiety is derived from animal fats, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.
PE(20:4(5Z,8Z,11Z,14Z)/P-18:1(9Z))
PE(20:4(5Z,8Z,11Z,14Z)/P-18:1(9Z)) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(20:4(5Z,8Z,11Z,14Z)/P-18:1(9Z)), in particular, consists of one chain of arachidonic acid at the C-1 position and one chain of plasmalogen 18:1n9 at the C-2 position. The arachidonic acid moiety is derived from animal fats and eggs, while the plasmalogen 18:1n9 moiety is derived from animal fats, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PEs are neutral zwitterions at physiological pH. They mostly have palmitic or stearic acid on carbon 1 and a long chain unsaturated fatty acid (e.g. 18:2, 20:4 and 22:6) on carbon 2. PE synthesis can occur via two pathways. The first requires that ethanolamine be activated by phosphorylation and then coupled to CDP. The ethanolamine is then transferred from CDP-ethanolamine to phosphatidic acid to yield PE. The second involves the decarboxylation of PS. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids. PE(20:4(5Z,8Z,11Z,14Z)/P-18:1(9Z)) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(20:4(5Z,8Z,11Z,14Z)/P-18:1(9Z)), in particular, consists of one chain of arachidonic acid at the C-1 position and one chain of plasmalogen 18:1n9 at the C-2 position. The arachidonic acid moiety is derived from animal fats and eggs, while the plasmalogen 18:1n9 moiety is derived from animal fats, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.
PE(20:4(8Z,11Z,14Z,17Z)/P-18:1(11Z))
PE(20:4(8Z,11Z,14Z,17Z)/P-18:1(11Z)) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(20:4(8Z,11Z,14Z,17Z)/P-18:1(11Z)), in particular, consists of one chain of eicsoatetraenoic acid at the C-1 position and one chain of plasmalogen 18:1n7 at the C-2 position. The eicsoatetraenoic acid moiety is derived from fish oils, while the plasmalogen 18:1n7 moiety is derived from animal fats, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PEs are neutral zwitterions at physiological pH. They mostly have palmitic or stearic acid on carbon 1 and a long chain unsaturated fatty acid (e.g. 18:2, 20:4 and 22:6) on carbon 2. PE synthesis can occur via two pathways. The first requires that ethanolamine be activated by phosphorylation and then coupled to CDP. The ethanolamine is then transferred from CDP-ethanolamine to phosphatidic acid to yield PE. The second involves the decarboxylation of PS. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids.
PE(20:4(8Z,11Z,14Z,17Z)/P-18:1(9Z))
PE(20:4(8Z,11Z,14Z,17Z)/P-18:1(9Z)) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(20:4(8Z,11Z,14Z,17Z)/P-18:1(9Z)), in particular, consists of one chain of eicsoatetraenoic acid at the C-1 position and one chain of plasmalogen 18:1n9 at the C-2 position. The eicsoatetraenoic acid moiety is derived from fish oils, while the plasmalogen 18:1n9 moiety is derived from animal fats, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PEs are neutral zwitterions at physiological pH. They mostly have palmitic or stearic acid on carbon 1 and a long chain unsaturated fatty acid (e.g. 18:2, 20:4 and 22:6) on carbon 2. PE synthesis can occur via two pathways. The first requires that ethanolamine be activated by phosphorylation and then coupled to CDP. The ethanolamine is then transferred from CDP-ethanolamine to phosphatidic acid to yield PE. The second involves the decarboxylation of PS. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids. PE(20:4(8Z,11Z,14Z,17Z)/P-18:1(9Z)) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(20:4(8Z,11Z,14Z,17Z)/P-18:1(9Z)), in particular, consists of one chain of eicsoatetraenoic acid at the C-1 position and one chain of plasmalogen 18:1n9 at the C-2 position. The eicsoatetraenoic acid moiety is derived from fish oils, while the plasmalogen 18:1n9 moiety is derived from animal fats, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.
PE(20:5(5Z,8Z,11Z,14Z,17Z)/P-18:0)
PE(20:5(5Z,8Z,11Z,14Z,17Z)/P-18:0) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(20:5(5Z,8Z,11Z,14Z,17Z)/P-18:0), in particular, consists of one chain of eicosapentaenoic acid at the C-1 position and one chain of plasmalogen 18:0 at the C-2 position. The eicosapentaenoic acid moiety is derived from fish oils, liver and kidney, while the plasmalogen 18:0 moiety is derived from animal fats, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PEs are neutral zwitterions at physiological pH. They mostly have palmitic or stearic acid on carbon 1 and a long chain unsaturated fatty acid (e.g. 18:2, 20:4 and 22:6) on carbon 2. PE synthesis can occur via two pathways. The first requires that ethanolamine be activated by phosphorylation and then coupled to CDP. The ethanolamine is then transferred from CDP-ethanolamine to phosphatidic acid to yield PE. The second involves the decarboxylation of PS. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids. PE(20:5(5Z,8Z,11Z,14Z,17Z)/P-18:0) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(20:5(5Z,8Z,11Z,14Z,17Z)/P-18:0), in particular, consists of one chain of eicosapentaenoic acid at the C-1 position and one chain of plasmalogen 18:0 at the C-2 position. The eicosapentaenoic acid moiety is derived from fish oils, liver and kidney, while the plasmalogen 18:0 moiety is derived from animal fats, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.
PE(22:5(4Z,7Z,10Z,13Z,16Z)/P-16:0)
PE(22:5(4Z,7Z,10Z,13Z,16Z)/P-16:0) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(22:5(4Z,7Z,10Z,13Z,16Z)/P-16:0), in particular, consists of one chain of docosapentaenoic acid at the C-1 position and one chain of plasmalogen 16:0 at the C-2 position. The docosapentaenoic acid moiety is derived from animal fats and brain, while the plasmalogen 16:0 moiety is derived from animal fats, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PEs are neutral zwitterions at physiological pH. They mostly have palmitic or stearic acid on carbon 1 and a long chain unsaturated fatty acid (e.g. 18:2, 20:4 and 22:6) on carbon 2. PE synthesis can occur via two pathways. The first requires that ethanolamine be activated by phosphorylation and then coupled to CDP. The ethanolamine is then transferred from CDP-ethanolamine to phosphatidic acid to yield PE. The second involves the decarboxylation of PS. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids.
PE(22:5(7Z,10Z,13Z,16Z,19Z)/P-16:0)
PE(22:5(7Z,10Z,13Z,16Z,19Z)/P-16:0) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(22:5(7Z,10Z,13Z,16Z,19Z)/P-16:0), in particular, consists of one chain of docosapentaenoic acid at the C-1 position and one chain of plasmalogen 16:0 at the C-2 position. The docosapentaenoic acid moiety is derived from fish oils, while the plasmalogen 16:0 moiety is derived from animal fats, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PEs are neutral zwitterions at physiological pH. They mostly have palmitic or stearic acid on carbon 1 and a long chain unsaturated fatty acid (e.g. 18:2, 20:4 and 22:6) on carbon 2. PE synthesis can occur via two pathways. The first requires that ethanolamine be activated by phosphorylation and then coupled to CDP. The ethanolamine is then transferred from CDP-ethanolamine to phosphatidic acid to yield PE. The second involves the decarboxylation of PS. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids.
PE(P-16:0/22:5(7Z,10Z,13Z,16Z,19Z))
PE(P-16:0/22:5(7Z,10Z,13Z,16Z,19Z)) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(P-16:0/22:5(7Z,10Z,13Z,16Z,19Z)), in particular, consists of one chain of plasmalogen 16:0 at the C-1 position and one chain of docosapentaenoic acid at the C-2 position. The plasmalogen 16:0 moiety is derived from animal fats, liver and kidney, while the docosapentaenoic acid moiety is derived from fish oils. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PEs are neutral zwitterions at physiological pH. They mostly have palmitic or stearic acid on carbon 1 and a long chain unsaturated fatty acid (e.g. 18:2, 20:4 and 22:6) on carbon 2. PE synthesis can occur via two pathways. The first requires that ethanolamine be activated by phosphorylation and then coupled to CDP. The ethanolamine is then transferred from CDP-ethanolamine to phosphatidic acid to yield PE. The second involves the decarboxylation of PS. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids.
PE(P-18:0/20:5(5Z,8Z,11Z,14Z,17Z))
PE(P-18:0/20:5(5Z,8Z,11Z,14Z,17Z)) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(P-18:0/20:5(5Z,8Z,11Z,14Z,17Z)), in particular, consists of one chain of plasmalogen 18:0 at the C-1 position and one chain of eicosapentaenoic acid at the C-2 position. The plasmalogen 18:0 moiety is derived from animal fats, liver and kidney, while the eicosapentaenoic acid moiety is derived from fish oils, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PEs are neutral zwitterions at physiological pH. They mostly have palmitic or stearic acid on carbon 1 and a long chain unsaturated fatty acid (e.g. 18:2, 20:4 and 22:6) on carbon 2. PE synthesis can occur via two pathways. The first requires that ethanolamine be activated by phosphorylation and then coupled to CDP. The ethanolamine is then transferred from CDP-ethanolamine to phosphatidic acid to yield PE. The second involves the decarboxylation of PS. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids. PE(P-18:0/20:5(5Z,8Z,11Z,14Z,17Z)) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(P-18:0/20:5(5Z,8Z,11Z,14Z,17Z)), in particular, consists of one chain of plasmalogen 18:0 at the C-1 position and one chain of eicosapentaenoic acid at the C-2 position. The plasmalogen 18:0 moiety is derived from animal fats, liver and kidney, while the eicosapentaenoic acid moiety is derived from fish oils, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.
PE(P-18:1(11Z)/20:4(5Z,8Z,11Z,14Z))
PE(P-18:1(11Z)/20:4(5Z,8Z,11Z,14Z)) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(P-18:1(11Z)/20:4(5Z,8Z,11Z,14Z)), in particular, consists of one chain of plasmalogen 18:1n7 at the C-1 position and one chain of arachidonic acid at the C-2 position. The plasmalogen 18:1n7 moiety is derived from animal fats, liver and kidney, while the arachidonic acid moiety is derived from animal fats and eggs. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PEs are neutral zwitterions at physiological pH. They mostly have palmitic or stearic acid on carbon 1 and a long chain unsaturated fatty acid (e.g. 18:2, 20:4 and 22:6) on carbon 2. PE synthesis can occur via two pathways. The first requires that ethanolamine be activated by phosphorylation and then coupled to CDP. The ethanolamine is then transferred from CDP-ethanolamine to phosphatidic acid to yield PE. The second involves the decarboxylation of PS. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids. PE(P-18:1(11Z)/20:4(5Z,8Z,11Z,14Z)) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(P-18:1(11Z)/20:4(5Z,8Z,11Z,14Z)), in particular, consists of one chain of plasmalogen 18:1n7 at the C-1 position and one chain of arachidonic acid at the C-2 position. The plasmalogen 18:1n7 moiety is derived from animal fats, liver and kidney, while the arachidonic acid moiety is derived from animal fats and eggs. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.
PE(P-18:1(11Z)/20:4(8Z,11Z,14Z,17Z))
PE(P-18:1(11Z)/20:4(8Z,11Z,14Z,17Z)) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(P-18:1(11Z)/20:4(8Z,11Z,14Z,17Z)), in particular, consists of one chain of plasmalogen 18:1n7 at the C-1 position and one chain of eicsoatetraenoic acid at the C-2 position. The plasmalogen 18:1n7 moiety is derived from animal fats, liver and kidney, while the eicsoatetraenoic acid moiety is derived from fish oils. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PEs are neutral zwitterions at physiological pH. They mostly have palmitic or stearic acid on carbon 1 and a long chain unsaturated fatty acid (e.g. 18:2, 20:4 and 22:6) on carbon 2. PE synthesis can occur via two pathways. The first requires that ethanolamine be activated by phosphorylation and then coupled to CDP. The ethanolamine is then transferred from CDP-ethanolamine to phosphatidic acid to yield PE. The second involves the decarboxylation of PS. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids. PE(P-18:1(11Z)/20:4(8Z,11Z,14Z,17Z)) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(P-18:1(11Z)/20:4(8Z,11Z,14Z,17Z)), in particular, consists of one chain of plasmalogen 18:1n7 at the C-1 position and one chain of eicsoatetraenoic acid at the C-2 position. The plasmalogen 18:1n7 moiety is derived from animal fats, liver and kidney, while the eicsoatetraenoic acid moiety is derived from fish oils. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.
PE(P-18:1(9Z)/20:4(5Z,8Z,11Z,14Z))
PE(P-18:1(9Z)/20:4(5Z,8Z,11Z,14Z)) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(P-18:1(9Z)/20:4(5Z,8Z,11Z,14Z)), in particular, consists of one chain of plasmalogen 18:1n9 at the C-1 position and one chain of arachidonic acid at the C-2 position. The plasmalogen 18:1n9 moiety is derived from animal fats, liver and kidney, while the arachidonic acid moiety is derived from animal fats and eggs. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PEs are neutral zwitterions at physiological pH. They mostly have palmitic or stearic acid on carbon 1 and a long chain unsaturated fatty acid (e.g. 18:2, 20:4 and 22:6) on carbon 2. PE synthesis can occur via two pathways. The first requires that ethanolamine be activated by phosphorylation and then coupled to CDP. The ethanolamine is then transferred from CDP-ethanolamine to phosphatidic acid to yield PE. The second involves the decarboxylation of PS. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids.
PE(P-18:1(9Z)/20:4(8Z,11Z,14Z,17Z))
PE(P-18:1(9Z)/20:4(8Z,11Z,14Z,17Z)) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(P-18:1(9Z)/20:4(8Z,11Z,14Z,17Z)), in particular, consists of one chain of plasmalogen 18:1n9 at the C-1 position and one chain of eicsoatetraenoic acid at the C-2 position. The plasmalogen 18:1n9 moiety is derived from animal fats, liver and kidney, while the eicsoatetraenoic acid moiety is derived from fish oils. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PEs are neutral zwitterions at physiological pH. They mostly have palmitic or stearic acid on carbon 1 and a long chain unsaturated fatty acid (e.g. 18:2, 20:4 and 22:6) on carbon 2. PE synthesis can occur via two pathways. The first requires that ethanolamine be activated by phosphorylation and then coupled to CDP. The ethanolamine is then transferred from CDP-ethanolamine to phosphatidic acid to yield PE. The second involves the decarboxylation of PS. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids. PE(P-18:1(9Z)/20:4(8Z,11Z,14Z,17Z)) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(P-18:1(9Z)/20:4(8Z,11Z,14Z,17Z)), in particular, consists of one chain of plasmalogen 18:1n9 at the C-1 position and one chain of eicsoatetraenoic acid at the C-2 position. The plasmalogen 18:1n9 moiety is derived from animal fats, liver and kidney, while the eicsoatetraenoic acid moiety is derived from fish oils. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.
nonaprenyl-4-hydroxybenzoate
Nonaprenyl-4-hydroxybenzoate is a member of the class of compounds known as polyprenylphenols. Polyprenylphenols are compounds containing a polyisoprene chain attached to a phenol group. Nonaprenyl-4-hydroxybenzoate is practically insoluble (in water) and a weakly acidic compound (based on its pKa). Nonaprenyl-4-hydroxybenzoate can be found in a number of food items such as sweet potato, banana, shallot, and swamp cabbage, which makes nonaprenyl-4-hydroxybenzoate a potential biomarker for the consumption of these food products.
bacteriohopane-,32,33,34-triol-35-cyclitolguanine
C42H75N3O8 (749.5553870000001)
PE(16:0e/22:6)
2-[hydroxy-[(2S,3R,4E,8Z)-3-hydroxy-2-[[(6E,8Z,11Z,14Z)-5-oxoicosa-6,8,11,14-tetraenoyl]amino]heptadeca-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium
C42H74N2O7P+ (749.5233364000001)
2-[hydroxy-[(2S,3R,4E,8Z)-3-hydroxy-2-[[(5Z,8Z,11Z,13E)-15-oxoicosa-5,8,11,13-tetraenoyl]amino]heptadeca-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium
C42H74N2O7P+ (749.5233364000001)
2-[hydroxy-[(2S,3R,4E,8Z)-3-hydroxy-2-[[(5Z,8Z,11Z,14Z,16E,18R)-18-hydroxyicosa-5,8,11,14,16-pentaenoyl]amino]heptadeca-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium
C42H74N2O7P+ (749.5233364000001)
2-[hydroxy-[(2S,3R,4E,8Z)-3-hydroxy-2-[[(5Z,8Z,11Z,13E,17Z)-16-hydroxyicosa-5,8,11,13,17-pentaenoyl]amino]heptadeca-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium
C42H74N2O7P+ (749.5233364000001)
2-[hydroxy-[(2S,3R,4E,8Z)-3-hydroxy-2-[[(5Z,8Z,10E,14Z,17Z)-12-hydroxyicosa-5,8,10,14,17-pentaenoyl]amino]heptadeca-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium
C42H74N2O7P+ (749.5233364000001)
2-[hydroxy-[(2S,3R,4E,8Z)-3-hydroxy-2-[[(6E,8Z,11Z,14Z,17Z)-5-hydroxyicosa-6,8,11,14,17-pentaenoyl]amino]heptadeca-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium
C42H74N2O7P+ (749.5233364000001)
1-Hexadecanoyl-2-octadecanoyl-sn-glycero-3-phospho-(1-sn-glycerol)(1-)
A 1,2-diacyl-sn-glycero-3-phospho-(1-sn-glycerol)(1-) in which the 1- and 2-acyl groups are specified as hexadecanoyl (palmitoyl) and octadecanoyl (stearoyl) respectively; major species at pH 7.3.
2-[[(2S,3S,4R)-3,4-dihydroxy-15-methyl-2-(nonadecanoylamino)hexadecoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-hexadec-9-enoxy]propan-2-yl] (7Z,10Z,13Z,16Z,19Z)-docosa-7,10,13,16,19-pentaenoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoxy]propan-2-yl] (Z)-octadec-9-enoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(9Z,12Z)-octadeca-9,12-dienoxy]propan-2-yl] (8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-hexadecoxypropan-2-yl] (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoate
[3-[2-aminoethoxy(hydroxy)phosphoryl]oxy-2-hydroxypropyl] (20Z,23Z,26Z,29Z,32Z,35Z)-octatriaconta-20,23,26,29,32,35-hexaenoate
[2-[(8Z,11Z,14Z,17Z,20Z,23Z)-hexacosa-8,11,14,17,20,23-hexaenoyl]oxy-3-nonoxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
2-[2-[(12Z,15Z,18Z)-hexacosa-12,15,18-trienoyl]oxy-3-octanoyloxypropoxy]-2-[2-(trimethylazaniumyl)ethoxy]acetate
2-[2-[(11Z,14Z)-henicosa-11,14-dienoyl]oxy-3-[(Z)-tridec-9-enoyl]oxypropoxy]-2-[2-(trimethylazaniumyl)ethoxy]acetate
2-[2-[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoyl]oxy-3-octadecanoyloxypropoxy]-2-[2-(trimethylazaniumyl)ethoxy]acetate
2-[2-[(11Z,14Z)-icosa-11,14-dienoyl]oxy-3-[(Z)-tetradec-9-enoyl]oxypropoxy]-2-[2-(trimethylazaniumyl)ethoxy]acetate
2-[3-hexadecanoyloxy-2-[(9Z,12Z,15Z)-octadeca-9,12,15-trienoyl]oxypropoxy]-2-[2-(trimethylazaniumyl)ethoxy]acetate
2-[2-[(9Z,12Z)-nonadeca-9,12-dienoyl]oxy-3-[(Z)-pentadec-9-enoyl]oxypropoxy]-2-[2-(trimethylazaniumyl)ethoxy]acetate
2-[3-decanoyloxy-2-[(10Z,13Z,16Z)-tetracosa-10,13,16-trienoyl]oxypropoxy]-2-[2-(trimethylazaniumyl)ethoxy]acetate
2-[3-[(Z)-hexadec-9-enoyl]oxy-2-[(9Z,12Z)-octadeca-9,12-dienoyl]oxypropoxy]-2-[2-(trimethylazaniumyl)ethoxy]acetate
2-[2-[(11Z,14Z,17Z)-icosa-11,14,17-trienoyl]oxy-3-tetradecanoyloxypropoxy]-2-[2-(trimethylazaniumyl)ethoxy]acetate
2-[2-[(9Z,12Z)-hexadeca-9,12-dienoyl]oxy-3-[(Z)-octadec-9-enoyl]oxypropoxy]-2-[2-(trimethylazaniumyl)ethoxy]acetate
2-[2-[(9Z,12Z)-heptadeca-9,12-dienoyl]oxy-3-[(Z)-heptadec-9-enoyl]oxypropoxy]-2-[2-(trimethylazaniumyl)ethoxy]acetate
2-[2-[(10Z,13Z,16Z)-docosa-10,13,16-trienoyl]oxy-3-dodecanoyloxypropoxy]-2-[2-(trimethylazaniumyl)ethoxy]acetate
(4E,8E,12E)-3-hydroxy-2-[[(14Z,16Z)-2-hydroxydocosa-14,16-dienoyl]amino]docosa-4,8,12-triene-1-sulfonic acid
(4E,8E,12E)-3-hydroxy-2-[[(18Z,21Z)-2-hydroxytetracosa-18,21-dienoyl]amino]icosa-4,8,12-triene-1-sulfonic acid
(4E,8E,12E)-3-hydroxy-2-[[(11Z,14Z)-2-hydroxyicosa-11,14-dienoyl]amino]tetracosa-4,8,12-triene-1-sulfonic acid
(4E,8E,12E)-3-hydroxy-2-[[(10Z,12Z)-2-hydroxyoctadeca-10,12-dienoyl]amino]hexacosa-4,8,12-triene-1-sulfonic acid
(4E,8E,12E)-3-hydroxy-2-[[(11Z,14Z)-2-hydroxyhexacosa-11,14-dienoyl]amino]octadeca-4,8,12-triene-1-sulfonic acid
[3-[(8Z,11Z,14Z,17Z,20Z,23Z)-hexacosa-8,11,14,17,20,23-hexaenoxy]-2-nonanoyloxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
[2-heptanoyloxy-3-[(10Z,13Z,16Z,19Z,22Z,25Z)-octacosa-10,13,16,19,22,25-hexaenoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate
2-Amino-3-[hydroxy-(3-icosoxy-2-tetradecanoyloxypropoxy)phosphoryl]oxypropanoic acid
2-Amino-3-[(2-hexadecanoyloxy-3-octadecoxypropoxy)-hydroxyphosphoryl]oxypropanoic acid
2-Amino-3-[(3-hexadecoxy-2-octadecanoyloxypropoxy)-hydroxyphosphoryl]oxypropanoic acid
(4E,8E,12E)-2-[[(Z)-hexacos-15-enoyl]amino]-3-hydroxynonadeca-4,8,12-triene-1-sulfonic acid
C45H83NO5S (749.5991627999999)
(4E,8E)-2-[[(11Z,14Z)-henicosa-11,14-dienoyl]amino]-3-hydroxytetracosa-4,8-diene-1-sulfonic acid
C45H83NO5S (749.5991627999999)
(4E,8E)-3-hydroxy-2-[[(9Z,12Z)-nonadeca-9,12-dienoyl]amino]hexacosa-4,8-diene-1-sulfonic acid
C45H83NO5S (749.5991627999999)
(4E,8E,12E)-2-[[(Z)-henicos-11-enoyl]amino]-3-hydroxytetracosa-4,8,12-triene-1-sulfonic acid
C45H83NO5S (749.5991627999999)
(4E,8E,12E)-3-hydroxy-2-[[(Z)-icos-11-enoyl]amino]pentacosa-4,8,12-triene-1-sulfonic acid
C45H83NO5S (749.5991627999999)
(E)-2-[[(12Z,15Z,18Z)-hexacosa-12,15,18-trienoyl]amino]-3-hydroxynonadec-4-ene-1-sulfonic acid
C45H83NO5S (749.5991627999999)
(4E,8E)-2-[[(15Z,18Z)-hexacosa-15,18-dienoyl]amino]-3-hydroxynonadeca-4,8-diene-1-sulfonic acid
C45H83NO5S (749.5991627999999)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoxy]propan-2-yl] (13Z,16Z)-docosa-13,16-dienoate
3-hydroxy-2-[[(8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoyl]amino]pentacosane-1-sulfonic acid
C45H83NO5S (749.5991627999999)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(11Z,14Z)-icosa-11,14-dienoxy]propan-2-yl] (6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoate
(4E,8E,12E)-3-hydroxy-2-[[(Z)-nonadec-9-enoyl]amino]hexacosa-4,8,12-triene-1-sulfonic acid
C45H83NO5S (749.5991627999999)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-decoxypropan-2-yl] (10Z,13Z,16Z,19Z,22Z,25Z)-octacosa-10,13,16,19,22,25-hexaenoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-tetradecoxypropan-2-yl] (6Z,9Z,12Z,15Z,18Z,21Z)-tetracosa-6,9,12,15,18,21-hexaenoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(9Z,12Z,15Z,18Z,21Z)-tetracosa-9,12,15,18,21-pentaenoxy]propan-2-yl] (Z)-tetradec-9-enoate
(E)-3-hydroxy-2-[[(11Z,14Z,17Z)-icosa-11,14,17-trienoyl]amino]pentacos-4-ene-1-sulfonic acid
C45H83NO5S (749.5991627999999)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoxy]propan-2-yl] (10Z,13Z,16Z)-docosa-10,13,16-trienoate
(4E,8E)-3-hydroxy-2-[[(11Z,14Z)-icosa-11,14-dienoyl]amino]pentacosa-4,8-diene-1-sulfonic acid
C45H83NO5S (749.5991627999999)
(4E,8E)-2-[[(13Z,16Z)-docosa-13,16-dienoyl]amino]-3-hydroxytricosa-4,8-diene-1-sulfonic acid
C45H83NO5S (749.5991627999999)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(13Z,16Z)-docosa-13,16-dienoxy]propan-2-yl] (4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoate
(4E,8E,12E)-2-[[(Z)-docos-13-enoyl]amino]-3-hydroxytricosa-4,8,12-triene-1-sulfonic acid
C45H83NO5S (749.5991627999999)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-tetradec-9-enoxy]propan-2-yl] (9Z,12Z,15Z,18Z,21Z)-tetracosa-9,12,15,18,21-pentaenoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-dodecoxypropan-2-yl] (8Z,11Z,14Z,17Z,20Z,23Z)-hexacosa-8,11,14,17,20,23-hexaenoate
(E)-2-[[(10Z,13Z,16Z)-docosa-10,13,16-trienoyl]amino]-3-hydroxytricos-4-ene-1-sulfonic acid
C45H83NO5S (749.5991627999999)
(E)-3-hydroxy-2-[[(10Z,13Z,16Z)-tetracosa-10,13,16-trienoyl]amino]henicos-4-ene-1-sulfonic acid
C45H83NO5S (749.5991627999999)
3-hydroxy-2-[[(12Z,15Z,18Z,21Z)-tetracosa-12,15,18,21-tetraenoyl]amino]henicosane-1-sulfonic acid
C45H83NO5S (749.5991627999999)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-icos-11-enoxy]propan-2-yl] (3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoate
(4E,8E,12E)-3-hydroxy-2-[[(Z)-tetracos-13-enoyl]amino]henicosa-4,8,12-triene-1-sulfonic acid
C45H83NO5S (749.5991627999999)
2-[[(14Z,17Z,20Z,23Z)-hexacosa-14,17,20,23-tetraenoyl]amino]-3-hydroxynonadecane-1-sulfonic acid
C45H83NO5S (749.5991627999999)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(10Z,13Z,16Z,19Z,22Z,25Z)-octacosa-10,13,16,19,22,25-hexaenoxy]propan-2-yl] decanoate
(4E,8E)-3-hydroxy-2-[[(13Z,16Z)-tetracosa-13,16-dienoyl]amino]henicosa-4,8-diene-1-sulfonic acid
C45H83NO5S (749.5991627999999)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(6Z,9Z,12Z,15Z,18Z,21Z)-tetracosa-6,9,12,15,18,21-hexaenoxy]propan-2-yl] tetradecanoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(8Z,11Z,14Z,17Z,20Z,23Z)-hexacosa-8,11,14,17,20,23-hexaenoxy]propan-2-yl] dodecanoate
2-[[(10Z,13Z,16Z,19Z)-docosa-10,13,16,19-tetraenoyl]amino]-3-hydroxytricosane-1-sulfonic acid
C45H83NO5S (749.5991627999999)
[3-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoxy]-2-[(9Z,12Z)-nonadeca-9,12-dienoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
[3-[(6Z,9Z,12Z,15Z,18Z,21Z)-tetracosa-6,9,12,15,18,21-hexaenoxy]-2-undecanoyloxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
[2-[(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoyl]oxy-3-tridecoxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
2-Amino-3-[hydroxy-(3-nonadecoxy-2-pentadecanoyloxypropoxy)phosphoryl]oxypropanoic acid
2-Amino-3-[hydroxy-(3-tricosoxy-2-undecanoyloxypropoxy)phosphoryl]oxypropanoic acid
[3-[(9Z,12Z)-heptadeca-9,12-dienoxy]-2-[(6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
2-Amino-3-[(3-decoxy-2-tetracosanoyloxypropoxy)-hydroxyphosphoryl]oxypropanoic acid
2-Amino-3-[(2-heptadecanoyloxy-3-heptadecoxypropoxy)-hydroxyphosphoryl]oxypropanoic acid
2-Amino-3-[(2-henicosanoyloxy-3-tridecoxypropoxy)-hydroxyphosphoryl]oxypropanoic acid
2-Amino-3-[(2-docosanoyloxy-3-dodecoxypropoxy)-hydroxyphosphoryl]oxypropanoic acid
[2-[(6Z,9Z,12Z,15Z,18Z,21Z)-tetracosa-6,9,12,15,18,21-hexaenoyl]oxy-3-undecoxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
2-Amino-3-[hydroxy-(2-nonadecanoyloxy-3-pentadecoxypropoxy)phosphoryl]oxypropanoic acid
2-Amino-3-[(3-docosoxy-2-dodecanoyloxypropoxy)-hydroxyphosphoryl]oxypropanoic acid
2-Amino-3-[hydroxy-(2-icosanoyloxy-3-tetradecoxypropoxy)phosphoryl]oxypropanoic acid
2-Amino-3-[(2-decanoyloxy-3-tetracosoxypropoxy)-hydroxyphosphoryl]oxypropanoic acid
[2-[(5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoyl]oxy-3-[(Z)-pentadec-9-enoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate
[2-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoyl]oxy-3-[(9Z,12Z)-nonadeca-9,12-dienoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate
2-Amino-3-[(3-henicosoxy-2-tridecanoyloxypropoxy)-hydroxyphosphoryl]oxypropanoic acid
2-Amino-3-[hydroxy-(2-tricosanoyloxy-3-undecoxypropoxy)phosphoryl]oxypropanoic acid
[2-[(7Z,10Z,13Z,16Z,19Z)-docosa-7,10,13,16,19-pentaenoyl]oxy-3-[(Z)-tridec-9-enoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate
[3-[(Z)-heptadec-9-enoxy]-2-[(3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
2-[4-[3-[(10Z,13Z,16Z)-docosa-10,13,16-trienoyl]oxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoylamino]acetic acid
2-[4-(10,13-dimethyl-3-octadecanoyloxy-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoylamino]ethanesulfonic acid
2-[4-[3-[(Z)-heptadec-9-enoyl]oxy-12-hydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoylamino]ethanesulfonic acid
4-[2-[(15Z,18Z)-hexacosa-15,18-dienoyl]oxy-3-nonanoyloxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2-[(Z)-henicos-11-enoyl]oxy-3-[(Z)-tetradec-9-enoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[3-heptadecanoyloxy-2-[(9Z,12Z)-octadeca-9,12-dienoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[3-[(Z)-heptadec-9-enoyl]oxy-2-[(Z)-octadec-9-enoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2-[(9Z,12Z)-heptadeca-9,12-dienoyl]oxy-3-octadecanoyloxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2-[(Z)-docos-13-enoyl]oxy-3-[(Z)-tridec-9-enoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2-[(13Z,16Z)-tetracosa-13,16-dienoyl]oxy-3-undecanoyloxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[3-hexadecanoyloxy-2-[(9Z,12Z)-nonadeca-9,12-dienoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2-[(13Z,16Z)-docosa-13,16-dienoyl]oxy-3-tridecanoyloxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2-[(Z)-icos-11-enoyl]oxy-3-[(Z)-pentadec-9-enoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2-[(11Z,14Z)-henicosa-11,14-dienoyl]oxy-3-tetradecanoyloxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2-[(9Z,12Z)-hexadeca-9,12-dienoyl]oxy-3-nonadecanoyloxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2-[(3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoyl]oxy-3-[(6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2-[(11Z,14Z)-icosa-11,14-dienoyl]oxy-3-pentadecanoyloxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[3-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoyl]oxy-2-[(5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[3-[(Z)-hexadec-9-enoyl]oxy-2-[(Z)-nonadec-9-enoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(7Z,10Z,13Z,16Z,19Z)-docosa-7,10,13,16,19-pentaenoxy]propan-2-yl] (Z)-hexadec-9-enoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(10Z,13Z,16Z)-docosa-10,13,16-trienoxy]propan-2-yl] (7Z,10Z,13Z)-hexadeca-7,10,13-trienoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(10Z,13Z,16Z,19Z)-docosa-10,13,16,19-tetraenoxy]propan-2-yl] (9Z,12Z)-hexadeca-9,12-dienoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoxy]propan-2-yl] (9Z,12Z)-octadeca-9,12-dienoate
[3-[(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoxy]-2-tridecanoyloxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
[2-[(Z)-heptadec-9-enoyl]oxy-3-[(3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate
[2-[(9Z,12Z)-heptadeca-9,12-dienoyl]oxy-3-[(6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate
[3-[(7Z,10Z,13Z,16Z,19Z)-docosa-7,10,13,16,19-pentaenoxy]-2-[(Z)-tridec-9-enoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(11Z,14Z,17Z)-icosa-11,14,17-trienoxy]propan-2-yl] (9Z,12Z,15Z)-octadeca-9,12,15-trienoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(9Z,12Z,15Z)-octadeca-9,12,15-trienoxy]propan-2-yl] (11Z,14Z,17Z)-icosa-11,14,17-trienoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(9Z,12Z)-hexadeca-9,12-dienoxy]propan-2-yl] (10Z,13Z,16Z,19Z)-docosa-10,13,16,19-tetraenoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoxy]propan-2-yl] (Z)-icos-11-enoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoxy]propan-2-yl] (11Z,14Z)-icosa-11,14-dienoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-octadec-9-enoxy]propan-2-yl] (5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoate
[3-[(5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoxy]-2-[(Z)-pentadec-9-enoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoxy]propan-2-yl] hexadecanoate
(4Z,7Z)-N-[(4E,8E)-3-hydroxy-1-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxydocosa-4,8-dien-2-yl]hexadeca-4,7-dienamide
(14Z,16Z)-N-[(4E,8E)-3-hydroxy-1-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhexadeca-4,8-dien-2-yl]docosa-14,16-dienamide
(Z)-N-[(4E,8E,12E)-3-hydroxy-1-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyheptadeca-4,8,12-trien-2-yl]henicos-9-enamide
(Z)-N-[(4E,8E,12E)-3-hydroxy-1-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhexadeca-4,8,12-trien-2-yl]docos-11-enamide
(Z)-N-[(4E,8E,12E)-3-hydroxy-1-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxydocosa-4,8,12-trien-2-yl]hexadec-7-enamide
(Z)-N-[(4E,8E,12E)-3-hydroxy-1-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhexacosa-4,8,12-trien-2-yl]dodec-5-enamide
(Z)-N-[(4E,8E,12E)-3-hydroxy-1-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxytetradeca-4,8,12-trien-2-yl]tetracos-11-enamide
(18Z,21Z)-N-[(4E,8E)-3-hydroxy-1-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxytetradeca-4,8-dien-2-yl]tetracosa-18,21-dienamide
(10Z,12Z)-N-[(4E,8E)-3-hydroxy-1-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyicosa-4,8-dien-2-yl]octadeca-10,12-dienamide
(Z)-N-[(4E,8E,12E)-3-hydroxy-1-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypentacosa-4,8,12-trien-2-yl]tridec-8-enamide
(Z)-N-[(4E,8E,12E)-3-hydroxy-1-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyicosa-4,8,12-trien-2-yl]octadec-11-enamide
(Z)-N-[(4E,8E,12E)-3-hydroxy-1-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypentadeca-4,8,12-trien-2-yl]tricos-11-enamide
(9E,12E)-N-[(2S,3R,4E,8E)-3-hydroxy-1-[(2S,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyicosa-4,8-dien-2-yl]octadeca-9,12-dienamide
4-[3-[(7E,9E,11E,13E,15E,17E,19E)-docosa-7,9,11,13,15,17,19-heptaenoyl]oxy-2-[(7E,9E)-tetradeca-7,9-dienoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2-[(E)-henicos-9-enoyl]oxy-3-[(E)-tetradec-9-enoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[3-[(E)-hexadec-7-enoyl]oxy-2-[(E)-nonadec-9-enoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2-[(4E,7E,10E,13E,16E,19E)-docosa-4,7,10,13,16,19-hexaenoyl]oxy-3-[(5E,8E,11E)-tetradeca-5,8,11-trienoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2-heptadecanoyloxy-3-[(10E,12E)-octadeca-10,12-dienoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[3-[(4E,7E)-deca-4,7-dienoyl]oxy-2-[(5E,8E,11E,14E,17E,20E,23E)-hexacosa-5,8,11,14,17,20,23-heptaenoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[3-[(6E,9E)-dodeca-6,9-dienoyl]oxy-2-tricosanoyloxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2-[(E)-tetracos-11-enoyl]oxy-3-[(E)-undec-4-enoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2-[(E)-dodec-5-enoyl]oxy-3-[(E)-tricos-11-enoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[3-[(11E,14E)-icosa-11,14-dienoyl]oxy-2-pentadecanoyloxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[3-[(E)-icos-11-enoyl]oxy-2-[(E)-pentadec-9-enoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
[(2R)-1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(E)-hexadec-1-enoxy]propan-2-yl] (7E,10E,13E,16E,19E)-docosa-7,10,13,16,19-pentaenoate
4-[2-[(14E,16E)-docosa-14,16-dienoyl]oxy-3-tridecanoyloxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2-[(E)-heptadec-7-enoyl]oxy-3-[(E)-octadec-11-enoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[3-[(9E,11E)-henicosa-9,11-dienoyl]oxy-2-tetradecanoyloxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2-[(18E,21E)-tetracosa-18,21-dienoyl]oxy-3-undecanoyloxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[3-[(4E,7E)-deca-4,7-dienoyl]oxy-2-pentacosanoyloxypropoxy]-2-(trimethylazaniumyl)butanoate
[(2R)-1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(E)-hexadec-1-enoxy]propan-2-yl] (4E,7E,10E,13E,16E)-docosa-4,7,10,13,16-pentaenoate
4-[2-[(9E,11E,13E)-hexadeca-9,11,13-trienoyl]oxy-3-[(7E,9E,11E,13E,15E,17E)-icosa-7,9,11,13,15,17-hexaenoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2-[(E)-hexadec-7-enoyl]oxy-3-[(E)-nonadec-9-enoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[3-heptadecanoyloxy-2-[(10E,12E)-octadeca-10,12-dienoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[3-[(7E,9E,11E,13E,15E)-octadeca-7,9,11,13,15-pentaenoyl]oxy-2-[(9E,11E,13E,15E)-octadeca-9,11,13,15-tetraenoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
[(2R)-1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(E)-octadec-1-enoxy]propan-2-yl] (5E,8E,11E,14E,17E)-icosa-5,8,11,14,17-pentaenoate
4-[2-[(9E,11E)-henicosa-9,11-dienoyl]oxy-3-tetradecanoyloxypropoxy]-2-(trimethylazaniumyl)butanoate
2-[hydroxy-[(2S,3R,4E,6E)-3-hydroxy-2-[[(5E,8E,11E,14E)-tetracosa-5,8,11,14-tetraenoyl]amino]tetradeca-4,6-dienoxy]phosphoryl]oxyethyl-trimethylazanium
4-[2-[(7E,9E,11E,13E,15E)-octadeca-7,9,11,13,15-pentaenoyl]oxy-3-[(9E,11E,13E,15E)-octadeca-9,11,13,15-tetraenoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[3-[(E)-henicos-9-enoyl]oxy-2-[(E)-tetradec-9-enoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[3-[(7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoyl]oxy-2-[(5E,8E,11E,14E,17E)-icosa-5,8,11,14,17-pentaenoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[3-icosanoyloxy-2-[(9E,12E)-pentadeca-9,12-dienoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[3-[(E)-docos-11-enoyl]oxy-2-[(E)-tridec-8-enoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
2-[hydroxy-[(2S,3R,4E,8E)-3-hydroxy-2-[[(5E,8E,11E,14E)-tetracosa-5,8,11,14-tetraenoyl]amino]tetradeca-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium
4-[3-[(4E,7E)-hexadeca-4,7-dienoyl]oxy-2-nonadecanoyloxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[3-[(E)-dodec-5-enoyl]oxy-2-[(E)-tricos-11-enoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2-decanoyloxy-3-[(11E,14E)-pentacosa-11,14-dienoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[3-dodecanoyloxy-2-[(14E,16E)-tricosa-14,16-dienoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[3-[(E)-heptadec-7-enoyl]oxy-2-[(E)-octadec-11-enoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2-icosanoyloxy-3-[(9E,12E)-pentadeca-9,12-dienoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2-[(E)-docos-11-enoyl]oxy-3-[(E)-tridec-8-enoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2-dodecanoyloxy-3-[(14E,16E)-tricosa-14,16-dienoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[3-[(E)-dec-4-enoyl]oxy-2-[(E)-pentacos-11-enoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2-henicosanoyloxy-3-[(7E,9E)-tetradeca-7,9-dienoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2-[(4E,7E)-hexadeca-4,7-dienoyl]oxy-3-nonadecanoyloxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2-[(4E,7E)-deca-4,7-dienoyl]oxy-3-[(5E,8E,11E,14E,17E,20E,23E)-hexacosa-5,8,11,14,17,20,23-heptaenoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[3-[(14E,16E)-docosa-14,16-dienoyl]oxy-2-tridecanoyloxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2-[(3E,6E,9E)-dodeca-3,6,9-trienoyl]oxy-3-[(6E,9E,12E,15E,18E,21E)-tetracosa-6,9,12,15,18,21-hexaenoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[3-decanoyloxy-2-[(11E,14E)-pentacosa-11,14-dienoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2-[(7E,9E,11E,13E,15E,17E,19E)-docosa-7,9,11,13,15,17,19-heptaenoyl]oxy-3-[(7E,9E)-tetradeca-7,9-dienoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[3-hexadecanoyloxy-2-[(7E,9E)-nonadeca-7,9-dienoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2-[(E)-icos-11-enoyl]oxy-3-[(E)-pentadec-9-enoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2-[(E)-dec-4-enoyl]oxy-3-[(E)-pentacos-11-enoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[3-henicosanoyloxy-2-[(7E,9E)-tetradeca-7,9-dienoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[3-[(5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoyl]oxy-2-[(5E,8E,11E,14E)-icosa-5,8,11,14-tetraenoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2-[(5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoyl]oxy-3-[(5E,8E,11E,14E)-icosa-5,8,11,14-tetraenoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
(5E,8E,11E,14E)-N-[(2S,3R)-3-hydroxy-1-[(2S,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxytetradecan-2-yl]tetracosa-5,8,11,14-tetraenamide
4-[2-[(11E,14E)-icosa-11,14-dienoyl]oxy-3-pentadecanoyloxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2-[(6E,9E)-dodeca-6,9-dienoyl]oxy-3-tricosanoyloxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[3-[(9E,11E,13E)-hexadeca-9,11,13-trienoyl]oxy-2-[(7E,9E,11E,13E,15E,17E)-icosa-7,9,11,13,15,17-hexaenoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2-[(7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoyl]oxy-3-[(5E,8E,11E,14E,17E)-icosa-5,8,11,14,17-pentaenoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[3-[(18E,21E)-tetracosa-18,21-dienoyl]oxy-2-undecanoyloxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[3-[(11E,14E)-heptadeca-11,14-dienoyl]oxy-2-octadecanoyloxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2-hexadecanoyloxy-3-[(7E,9E)-nonadeca-7,9-dienoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2-[(4E,7E)-deca-4,7-dienoyl]oxy-3-pentacosanoyloxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[3-[(E)-tetracos-11-enoyl]oxy-2-[(E)-undec-4-enoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[3-[(3E,6E,9E)-dodeca-3,6,9-trienoyl]oxy-2-[(6E,9E,12E,15E,18E,21E)-tetracosa-6,9,12,15,18,21-hexaenoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[3-[(4E,7E,10E,13E,16E,19E)-docosa-4,7,10,13,16,19-hexaenoyl]oxy-2-[(5E,8E,11E)-tetradeca-5,8,11-trienoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2-[(11E,14E)-heptadeca-11,14-dienoyl]oxy-3-octadecanoyloxypropoxy]-2-(trimethylazaniumyl)butanoate
2-[[(4E,8E)-2-[[(14Z,17Z,20Z,23Z)-hexacosa-14,17,20,23-tetraenoyl]amino]-3-hydroxydodeca-4,8-dienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(4E,8E,12E)-3-hydroxy-2-[[(11Z,14Z,17Z)-icosa-11,14,17-trienoyl]amino]octadeca-4,8,12-trienoxy]phosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(4E,8E)-3-hydroxy-2-[[(12Z,15Z,18Z,21Z)-tetracosa-12,15,18,21-tetraenoyl]amino]tetradeca-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(E)-3-hydroxy-2-[[(13Z,16Z,19Z,22Z,25Z)-octacosa-13,16,19,22,25-pentaenoyl]amino]dec-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[3-hydroxy-2-[[(6Z,9Z,12Z,15Z,18Z,21Z)-tetracosa-6,9,12,15,18,21-hexaenoyl]amino]tetradecoxy]phosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[3-hydroxy-2-[[(10Z,13Z,16Z,19Z,22Z,25Z)-octacosa-10,13,16,19,22,25-hexaenoyl]amino]decoxy]phosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(4E,8E)-3-hydroxy-2-[[(8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoyl]amino]octadeca-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium
2-[[(4E,8E)-2-[[(10Z,13Z,16Z,19Z)-docosa-10,13,16,19-tetraenoyl]amino]-3-hydroxyhexadeca-4,8-dienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[2-[[(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoyl]amino]-3-hydroxyhexadecoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(4E,8E,12E)-3-hydroxy-2-[[(9Z,12Z,15Z)-octadeca-9,12,15-trienoyl]amino]icosa-4,8,12-trienoxy]phosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(E)-3-hydroxy-2-[[(5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoyl]amino]octadec-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[3-hydroxy-2-[[(12Z,15Z,18Z,21Z,24Z,27Z)-triaconta-12,15,18,21,24,27-hexaenoyl]amino]octoxy]phosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(E)-3-hydroxy-2-[[(9Z,12Z,15Z,18Z,21Z)-tetracosa-9,12,15,18,21-pentaenoyl]amino]tetradec-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
2-[[(4E,8E)-2-[[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoyl]amino]-3-hydroxydocosa-4,8-dienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(E)-3-hydroxy-2-[[(3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoyl]amino]icos-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
2-[[(4E,8E,12E)-2-[[(10Z,13Z,16Z)-docosa-10,13,16-trienoyl]amino]-3-hydroxyhexadeca-4,8,12-trienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[(E)-2-[[(7Z,10Z,13Z,16Z,19Z)-docosa-7,10,13,16,19-pentaenoyl]amino]-3-hydroxyhexadec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[3,4-Dihydroxy-2-(octadecanoylamino)octadecoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[(E)-2-[[(11Z,14Z,17Z,20Z,23Z)-hexacosa-11,14,17,20,23-pentaenoyl]amino]-3-hydroxydodec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(4E,8E)-3-hydroxy-2-[[(6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoyl]amino]icosa-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(E)-3-hydroxy-2-[[(15Z,18Z,21Z,24Z,27Z)-triaconta-15,18,21,24,27-pentaenoyl]amino]oct-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
2-[[2-[[(8Z,11Z,14Z,17Z,20Z,23Z)-hexacosa-8,11,14,17,20,23-hexaenoyl]amino]-3-hydroxydodecoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(4E,8E,12E)-3-hydroxy-2-[[(10Z,13Z,16Z)-tetracosa-10,13,16-trienoyl]amino]tetradeca-4,8,12-trienoxy]phosphoryl]oxyethyl-trimethylazanium
2-[[(4E,8E,12E)-2-[[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoyl]amino]-3-hydroxydocosa-4,8,12-trienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-hexadecanoyl-1-octadecanoyl-sn-glycero-3-phospho-(1-sn-glycerol)(1-)
A 1,2-diacyl-sn-glycero-3-phospho-(1-sn-glycerol)(1-) in which the 1- and 2-acyl groups are specified as octadecanoyl (stearoyl) and hexadecanoyl (palmitoyl) respectively; major species at pH 7.3.
1-octadecadienyl-2-icosatetraenoyl-sn-glycero-3-phosphoethanolamine
A 1-(alk-1-enyl)-2-acyl-sn-glycero-3-phosphoethanolamine in which the alk-1-enyl and acyl groups are specified as octadecadienyl and icosatetraenoyl respectively.
phosphatidylethanolamine P-38:5
A 1-(alk-1-enyl)-2-acyl-sn-glycero-3-phosphoethanolamine zwitterion in which the alk-1-enyl and acyl groups at positions 1 and 2 contain 38 carbon atoms in total with 5 additional double bonds.
MePC(34:6)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
Hex1Cer(38:4)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
Hex1Cer(37:5)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
dMePE(36:6)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
n-[(2s,3r)-3-hydroxy-1-[(2s,4r)-2-{[(1s)-1-{[(1s)-3-hydroxy-1-{[(2s)-1-oxopropan-2-yl]-c-hydroxycarbonimidoyl}propyl]-c-hydroxycarbonimidoyl}-2-methylpropyl]-c-hydroxycarbonimidoyl}-4-methylpyrrolidin-1-yl]-1-oxobutan-2-yl]octadec-9-enimidic acid
(9z)-n-[(2s,3r)-3-hydroxy-1-[(2s,4r)-2-{[(1s)-1-{[(1s)-3-hydroxy-1-{[(2s)-1-oxopropan-2-yl]-c-hydroxycarbonimidoyl}propyl]-c-hydroxycarbonimidoyl}-2-methylpropyl]-c-hydroxycarbonimidoyl}-4-methylpyrrolidin-1-yl]-1-oxobutan-2-yl]octadec-9-enimidic acid
n-[3-hydroxy-1-(2-{[1-({3-hydroxy-1-[(1-oxopropan-2-yl)-c-hydroxycarbonimidoyl]propyl}-c-hydroxycarbonimidoyl)-2-methylpropyl]-c-hydroxycarbonimidoyl}-4-methylpyrrolidin-1-yl)-1-oxobutan-2-yl]octadec-9-enimidic acid
7-[(4s,6r,10s)-11-[(4-carbamimidamidobutoxy)carbonyl]-10-methyl-7,9,12-triazatricyclo[6.3.1.0⁴,¹²]dodeca-1(11),8-dien-6-yl]heptyl (1s,6s,10r)-10-heptyl-6-methyl-7,9,12-triazatricyclo[6.3.1.0⁴,¹²]dodeca-4,7-diene-5-carboxylate
C41H67N9O4 (749.5315741999999)